0001935979 1 2026-05-04 2026-05-04 0001935979 2026-05-04 2026-05-04 0001935979 1 2026-05-04 2026-05-04 0001935979 2 2026-05-04 2026-05-04 iso4217:USD pure 0001935979 Biohaven Ltd. S-3 424B5 EX-FILING FEES N/A 333-295531 false Equity Common Shares, no par value per share true 350000000 0.0001381 48335 350000000 48335 0.00 17519.09 30815.91 The maximum aggregate offering price is being used to calculate the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended (the "Securities Act"). In accordance with Rule 456(b) and Rule 457(r) under the Securities Act, the registrant initially deferred payment of all of the registration fee for the Registration Statement on Form S-3ASR (File No. 333-295531) filed by the registrant on May 4, 2026. true true Biohaven Ltd. S-3 333-274822 2023-10-02 17519.09 Equity Common Shares, no par value per share 118693000 false true Biohaven Ltd S-3 333-274822 2024-08-16 44280 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The registrant previously registered the offer, sale and issuance of common shares having an aggregate offering price of up to $300,000,000 by means of a prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act on August 16, 2024 (the “prior prospectus supplement”), pursuant to the Company’s registration statement on Form S-3 (File No. 333-274822), filed on October 2, 2023 (the “2023 Registration Statement”), with the Securities and Exchange Commission. In connection with the filing of the prior prospectus supplement, the registrant paid filing fees of $44,280.00. As of the date of this prospectus supplement, common shares having an aggregate offering price of $118,693,000.00 remain unsold under the prior prospectus supplement. Pursuant to Rule 457(p), $17,519.09 of the filing fee previously paid with respect to the unsold securities under the prior prospectus supplement is being applied to the filing fee payable with respect to this prospectus supplement. The registrant has completed the offering that included the unsold common shares under the prior prospectus supplement and the 2023 Registration Statement.</span></div> <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The registrant previously registered the offer, sale and issuance of common shares having an aggregate offering price of up to $300,000,000 by means of a prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act on August 16, 2024 (the “prior prospectus supplement”), pursuant to the Company’s registration statement on Form S-3 (File No. 333-274822), filed on October 2, 2023 (the “2023 Registration Statement”), with the Securities and Exchange Commission. In connection with the filing of the prior prospectus supplement, the registrant paid filing fees of $44,280.00. As of the date of this prospectus supplement, common shares having an aggregate offering price of $118,693,000.00 remain unsold under the prior prospectus supplement. Pursuant to Rule 457(p), $17,519.09 of the filing fee previously paid with respect to the unsold securities under the prior prospectus supplement is being applied to the filing fee payable with respect to this prospectus supplement. The registrant has completed the offering that included the unsold common shares under the prior prospectus supplement and the 2023 Registration Statement.</span></div>